Regeneron Pharmaceuticals' Research & Development rose 1515.47% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.9 billion, marking a year-over-year increase of 1399.45%. This contributed to the annual value of $5.9 billion for FY2025, which is 1399.45% up from last year.
Regeneron Pharmaceuticals' Research & Development amounted to $1.6 billion in Q4 2025, which was up 1515.47% from $1.5 billion recorded in Q3 2025.
Regeneron Pharmaceuticals' 5-year Research & Development high stood at $1.6 billion for Q4 2025, and its period low was $665.4 million during Q3 2021.
In the last 5 years, Regeneron Pharmaceuticals' Research & Development had a median value of $1.1 billion in 2023 and averaged $1.1 billion.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Research & Development crashed by 280.46% in 2021, and later soared by 4141.81% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Research & Development stood at $737.6 million in 2021, then surged by 41.42% to $1.0 billion in 2022, then grew by 12.86% to $1.2 billion in 2023, then increased by 19.95% to $1.4 billion in 2024, then increased by 15.15% to $1.6 billion in 2025.
Its Research & Development stands at $1.6 billion for Q4 2025, versus $1.5 billion for Q3 2025 and $1.4 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value